OptiNose (OPTN) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of OptiNose (NASDAQ:OPTN) from a sell rating to a hold rating in a research note published on Wednesday.

According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company’s lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. “

Separately, ValuEngine raised shares of OptiNose from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $29.25.

OptiNose traded down $0.34, hitting $24.24, during trading on Wednesday, according to MarketBeat. The stock had a trading volume of 543 shares, compared to its average volume of 80,407. The company has a debt-to-equity ratio of 0.57, a current ratio of 9.66 and a quick ratio of 15.99. The company has a market cap of $978.29 million and a P/E ratio of -4.37. OptiNose has a one year low of $23.03 and a one year high of $25.00.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Monday, May 14th. The company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.07). The firm had revenue of $0.87 million for the quarter. equities research analysts expect that OptiNose will post -3.26 EPS for the current year.

In related news, CEO Peter K. Miller purchased 5,054 shares of the firm’s stock in a transaction dated Friday, March 16th. The stock was purchased at an average price of $18.58 per share, with a total value of $93,903.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 67.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of OPTN. Schwab Charles Investment Management Inc. purchased a new position in OptiNose during the fourth quarter valued at approximately $432,000. Peregrine Capital Management LLC purchased a new position in OptiNose during the fourth quarter valued at approximately $6,314,000. Kornitzer Capital Management Inc. KS purchased a new position in OptiNose during the fourth quarter valued at approximately $6,040,000. American Century Companies Inc. purchased a new position in OptiNose during the fourth quarter valued at approximately $1,745,000. Finally, Wells Fargo & Company MN purchased a new position in OptiNose during the fourth quarter valued at approximately $5,392,000. 29.86% of the stock is currently owned by institutional investors.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Prudential Financial Inc. Buys 256,526 Shares of CIT Group
Prudential Financial Inc. Buys 256,526 Shares of CIT Group
Berkshire Hills Bancorp, Inc.  Position Raised by Prudential Financial Inc.
Berkshire Hills Bancorp, Inc. Position Raised by Prudential Financial Inc.
Prudential Financial Inc. Raises Position in CNA Financial
Prudential Financial Inc. Raises Position in CNA Financial
Insider Buying: Groundstar Res  Director Acquires 685,000 Shares of Stock
Insider Buying: Groundstar Res Director Acquires 685,000 Shares of Stock
Ooma Inc  VP Sells $18,384.00 in Stock
Ooma Inc VP Sells $18,384.00 in Stock
Mackay Shields LLC Invests $1.13 Million in Hanesbrands
Mackay Shields LLC Invests $1.13 Million in Hanesbrands


Leave a Reply

© 2006-2018 Ticker Report. Google+.